Quentin Blackford, President and CEO, iRhythm Technologies : Yeah. Let me hit that last one, Bill, first on, the MCT filing running in parallel. I presume you mean in parallel with sort of remediation or the FDA coming back to close down the warning letter. And if that is what you're referring to, you're absolutely right. They will run-in parallel.